| Literature DB >> 29693969 |
Muna Maharjan1,2, Niresh Thapa, Raj Devi Adhikari, Marcia A Petrini, Kapendra Shekhar Amatya.
Abstract
Introduction: Worldwide breast cancer is the common invasive cancer among the females. The quality of life of women after treatment, which is often a mastectomy, is frequently decreased. Objective: To determine the life quality of Nepalese women post mastectomy. Materials andEntities:
Keywords: Breast cancer; EORTC; quality of life; mastectomy; nursing
Mesh:
Year: 2018 PMID: 29693969 PMCID: PMC6031789 DOI: 10.22034/APJCP.2018.19.4.1005
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Figure 1Conceptual Framework of QOL of Women Post Mastectomy Stress and Coping Framework
Socio- Demographic Characteristic of the Respondents n=107
| Socio-demographic Characteristics | Number | Percentage |
|---|---|---|
| Age | ||
| < 48 | 59 | 55.1 |
| > 49 | 48 | 44.9 |
| Mean±SD | 47.88±9.76 | |
| Marital status | ||
| Married | 93 | 86.9 |
| Widow | 10 | 9.3 |
| Single | 4 | 3.7 |
| Family type | ||
| Nuclear | 90 | 84.1 |
| Joint | 17 | 15.9 |
| Occupation | ||
| Homemaker | 64 | 59.8 |
| Service | 26 | 24.3 |
| Business | 14 | 13.1 |
| Agriculture | 3 | 2.8 |
| Education | ||
| Illiterate | 43 | 40.2 |
| Literate | 64 | 59.8 |
| Education level (n=64) | ||
| Primary level | 7 | 10.9 |
| Secondary level | 22 | 34.4 |
| Higher secondary level | 20 | 31.2 |
| Graduate (Bachelor level and above) | 15 | 23.4 |
| Family history of cancer | ||
| Cancer present | 8 | 7.5 |
| Cancer absent | 99 | 92.5 |
| Use of breast prosthesis | ||
| Using breast prosthesis | 34 | 31.8 |
| Not using breast prosthesis | 73 | 68.2 |
| Types of prosthesis using (n=34) | ||
| Sponge | 24 | 70.6 |
| Cloth | 7 | 20.6 |
| Silicon | 3 | 8.8 |
| Stage of cancer | ||
| Stage IIa | 54 | 50.5 |
| Stage IIb | 33 | 30.8 |
| Stage IIIa | 13 | 12.1 |
| Stage IIIb | 1 | 0.9 |
| Stage IIIc | 6 | 5.6 |
| Type of treatment received (multiple response) | ||
| Surgery | 107 | 100 |
| Chemotherapy | 107 | 100 |
| Radiotherapy | 83 | 77.6 |
| Hormonal therapy | 83 | 77.6 |
| Presence of comorbidity (n=18) | ||
| Hypertension | 9 | 50 |
| Diabetes | 7 | 38.8 |
| Diabetes and hypertension | 2 | 11.1 |
Scores of the Respondents on Various Items of QLQ C30 and BR23 Scale
| Variables | No of items | N | Poor <33.3 | Average 33.3-66.6 | Good >66.6 | Mean | SD |
|---|---|---|---|---|---|---|---|
| Global Health Status/QOL | |||||||
| Global health status/QOL | 2 | 107 | 0 | 0 | 107 | 79.43 | 11.86 |
| C-30 Functional Scales | |||||||
| Physical functioning | 5 | 107 | 0 | 0 | 107 | 90.21 | 6.09 |
| Role functioning | 2 | 107 | 0 | 0 | 107 | 98.28 | 5.08 |
| Emotional functioning | 4 | 107 | 0 | 0 | 107 | 93.06 | 6.21 |
| Cognitive functioning | 2 | 107 | 0 | 0 | 107 | 97.19 | 6.26 |
| Social functioning | 2 | 107 | 0 | 0 | 107 | 100 | 0 |
| BR-23 Functional Scales | |||||||
| Body image | 4 | 107 | 0 | 14 | 93 | 74.62 | 15.35 |
| Sexual functioning | 2 | 107 | 98 | 9 | 0 | 2.95 | 9.38 |
| Sexual enjoyment | 1 | 12 | 0 | 10 | 2 | 27.77 | 12.97 |
| Future perspective | 1 | 107 | 0 | 0 | 107 | 80.36 | 16.48 |
Scores of the Respondents on Symptoms Scales of QLQ C30 and BR23 Scale
| Variables | No of items | N | Good <33.3 | Average 33.3 -66.6 | Poor >66.6 | Mean | SD |
|---|---|---|---|---|---|---|---|
| C-30 Symptom Scales | |||||||
| Fatigue | 3 | 107 | 103 | 4 | 0 | 12.37 | 9.32 |
| Nausea/Vomiting | 2 | 107 | 107 | 0 | 0 | 0.46 | 2.76 |
| Pain | 2 | 107 | 106 | 1 | 0 | 7.47 | 8.63 |
| Dyspnoea | 1 | 107 | 104 | 3 | 0 | 0.93 | 6.2 |
| Insomnia | 1 | 107 | 91 | 16 | 0 | 4.98 | 11.94 |
| Appetite loss | 1 | 107 | 86 | 21 | 0 | 6.54 | 13.29 |
| Constipation | 1 | 107 | 104 | 3 | 0 | 0.93 | 5.52 |
| Diarrhea | 1 | 107 | 103 | 4 | 0 | 1.24 | 6.35 |
| Financial difficulties | 1 | 107 | 104 | 3 | 0 | 0.93 | 5.52 |
| BR-23 Symptom Scales | |||||||
| Systemic therapy side effects | 7 | 107 | 107 | 0 | 0 | 7.07 | 5.91 |
| Breast symptoms | 4 | 107 | 106 | 1 | 0 | 12.69 | 6.6 |
| Arm symptoms | 3 | 107 | 106 | 1 | 0 | 10.87 | 8.1 |
| Upset by hair loss | 1 | 50 | 32 | 18 | 0 | 12.66 | 17.67 |
Associations between Respondent’s Characteristics and QLQ C-30 and BR-23
| Characteristics | GHS | PF | RF | EF | CF | BI | SF | FU | ST |
|---|---|---|---|---|---|---|---|---|---|
| Age | |||||||||
| < 48 years | 83.33 (83.33 - 66.66) | 86.66 (100 -86.66) | 100 (100 -100) | 91.66 (91.66 -91.66) | 100 (100 -100) | 66.66 (75-66.66) | 0 | 66.66 (100-66.66) | 4.66 (9.66-0) |
| > 49 years | 79.16 (83.33 - 66.66) | 86.66 (93.33 -86.66) | 100 (100 -100) | 100 (100 -91.66) | 100 (100 -100) | 79.16 (100-66.66) | 0 | 100 (100-66.66) | 9.66 (14.33-4.66) |
| †P-value | 0.136 | 0.066 | 0.207 | 0.000* | 0.182 | 0.000* | 0.033* | 0.000* | 0.000* |
| Marital status | |||||||||
| Unmarried | 83.33 (95.83 - 83.33) | 100 (100 - 94.99) | NA | 91.66 (97.91- 85.41) | NA | 62.5 (87.49-43.74) | NA | 83.33 (100-66.66) | 2.22 (4.66-0) |
| Married | 83.33 (83.33 - 66.66) | 86.66 (93.33 -86.66) | NA | 91.66 (100-91.66) | NA | 66.66 (83.33-66.66) | NA | 66.66 (100-66.66) | 4.66 (9.66-4.66) |
| †P-value | 0.145 | 0.007* | 0.604 | 0.33 | 0.714 | 0.007* | |||
| Occupation | |||||||||
| Homemaker | 75 (83.33 - 66.66) | 86.66 (86.66-86.66) | 100 (100-100) | 91.66 (100-91.66) | 100 (100-100) | 75 (100-66.66) | 0 | 66.66 (100-66.66) | 9.66 (9.66-4.66) |
| Service/Business/Agriculture | 83.33 (91.66 – 66.66) | 93.33 (100-86.66) | 100 (100-100) | 91.66 (91.66-91.66) | 100 (100-100) | 66.66 (75-66.66) | 0 | 66.66 (100-66.66) | 4.66 (4.66-0) |
| †P-value | 0.033* | 0.013* | 0.307 | 0.027 | 0.241 | 0.003* | 0.079 | 0.283 | 0.008* |
| Education | |||||||||
| Illiterate | 75 (83.33 - 66.66) | 86.66 (93.33-86.66) | 100 (100-100) | 100 (100-91.66) | 100 (100-83.33) | 75 (100-66.66) | 0 | 100 (100-66.66) | 9.66 (14.33-4.66) |
| Literate | 83.33 (83.33 - 66.66) | 86.66 (100-86.66) | 100 (100-100) | 91.66 (91.66-91.66) | 100 (100-100) | 66.66 (75-66.66) | 0 | 66.66 (100-66.66) | 4.66 (9.66-0) |
| †P-value | 0.114 | 0.066 | 0.096 | 0.008* | 0.002* | 0.000* | 0.158 | 0.012* | 0.001* |
| Prosthesis Use | |||||||||
| Using breast prosthesis | 83.33 (100 – 72.91) | 86.66 (93.33-86.66) | 100 (100-100) | 91.66 (91.66-91.66) | 100 (100-100) | 66.66 (75-58.33) | 0 | 66.66 (100-66.66) | 4.66 (4.66-0) |
| Not using breast prosthesis | 75 (83.33 - 66.66) | 86.66 (96.66-86.66) | 100 (100-100) | 91.66 (100-91.66) | 100 (100-100) | 75 (100-66.66) | 0 | 66.66 (100-66.66) | 9.66 (11.99-4.66) |
| †P-value | 0.018* | 0.513 | 0.09 | 0.095 | 0.040* | 0.000* | 0.05 | 0.095 | 0.014* |
| Co-morbidity | |||||||||
| Present | 83.33 (93.74 - 66.66) | 86.66 (93.33-86.66) | 100 (100-100) | 100 (100-100) | 100 (100-83.33) | 100 (100-72.91) | 0 | 100 (100-100) | 9.66 (14.33-4.66) |
| Absent | 83.33 (83.33 - 66.66) | 86.66 (96.66-86.66) | 100 (100-100) | 91.66 (100-91.66) | 100 (100-100) | 66.66 (75-66.66) | 0 | 66.66 (100-66.66) | 4.66 (9.66-2.33) |
| †P-value | 0.607 | 0.477 | 0.33 | 0.000* | 0.041* | 0.000* | 0.541 | 0.000* | 0.033* |
Scores presented were median score and parentheses indicate minimum-maximum score; †, Mann-Whitney U test; GHS, global health status; PF, physical functioning; RF, role functioning; EF, emotional functioning; CF, cognitive functioning; BI, body image; SF, sexual functioning; FU, future perspective; ST, systemic therapy side effects; NA, not applicable